Assessment of a HER2 scoring system for gastric cancer: results from a validation study

20081,184 citationsJournal Article

Authors

Manfred Hofmann · Klinikum Kassel

O Stoss

Di Shi · Fudan University Shanghai Cancer Center

Reinhard Büttner · University Hospital Bonn

Marc J. van de Vijver · The Netherlands Cancer Institute

Woo‐Jae Kim · Seoul National University

Atsushi Ochiai · National Cancer Centre Japan

Abstract

IHC/FISH discrepancies were attributed to basolateral membranous immunoreactivity of glandular cells resulting in incomplete membranous reactivity and/or a higher rate of tumour heterogeneity in gastric cancer compared with breast cancer. With modifications to the IHC scoring system, the HercepTest is considered valid for the identification of HER2+ gastric tumours for this clinical trial. Correlation of HER2 scores with clinical outcomes will be needed to determine which patients might benefit from trastuzumab therapy.

Topics & Keywords

HER2/EGFR in Cancer Research Monoclonal and Polyclonal Antibodies Research Peptidase Inhibition and Analysis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Histopathology

Volume 52, Issue 7, pp. 797-805

DOI: 10.1111/j.1365-2559.2008.03028.x

Field-Weighted Citation Impact: 16.94